Investor Presentaiton

...with consistent financial performance over the years... Operating Revenue (cr.) Gross Profit (cr.) & Gross Profit Margin (%) 56.8% 50.2% CAGR:15.7% 49.9% O 1,376.2 42.7% 40.2% 781.1 1,134.2 1,000.1 912.7 566.4 502.1 767.2 389.6 308.4 FY17 FY18 FY19 FY20 FY21 EBITDA (*cr.) & EBITDA Margin 24.7% FY17 FY18 FY19 FY20 FY21 PAT (cr.) & PAT Margin 17.2% 17.0% 10.6% 13.2% 8.0% 8.6% 339.6 1.5% 5.8% 3.9% 192.3 132.1 11.3 44.7 78.4 35.8 80.4 120.8 238.5 FY17 FY18 FY19 FY20 FY21 FY17 FY18 FY19 FY20 FY21 ©2021 - Marksans Pharma Limited, All Rights Reserved. 20 20

View entire presentation